Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Karyopharm Therapeutics Inc.

www.karyopharm.com

Latest From Karyopharm Therapeutics Inc.

EU Accelerated Assessment – Hard To Get, Hard To Keep

It’s hard enough in the first place for companies to persuade the European Medicines Agency that their planned marketing authorization application should be fast-tracked. Many are also finding that after accelerated assessment is granted, it is taken away during the actual review.

Review Pathway Drug Review

US FDA, Advisory Committees Rarely Disagree

A Milbank Quarterly study and a Pink Sheet analysis show that disagreement between the US FDA and its advisory committee meetings doesn't happen often; it is even rarer for the agency to approve a drug against the advice from a panel.
Advisory Committees Approvals

Keeping Track: US Approvals For Xpovio And Xembify Highlight Short Holiday Week

The latest drug development news and highlights from our US FDA Performance Tracker.
Approvals Drug Review

Karyopharm’s Xpovio In Multiple Myeloma Priced At $22,000 Per Four-Week Cycle

Immediate interaction with US FDA after stressful advisory committee facilitated accelerated approval in fourth-line myeloma, company says. Four different dosing regimens will be priced at $22,000 for four weeks.

Approvals Commercial
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Infectious & Viral Diseases
  • Inflammation
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Karyopharm Therapeutics Inc.
  • Senior Management
  • Michael Kauffman, MD, PhD, CEO
    Michael Falvey, EVP, CFO
    Sharon Shacham, PhD, Pres. & CSO
    Christopher Primiano, EVP, CBO
    Anand Varadan, EVP, Chief Commercial Officer
  • Contact Info
  • Karyopharm Therapeutics Inc.
    Phone: (617) 658-0600
    85 Wells Ave.
    2nd Fl.
    Newton, MA 02459
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register